Plain-English translation of NCT06126406 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which are immune cells taken from your own body, specially designed in a lab to recognize and attack cancer cells. The treatment is being tested in patients with advanced cancers (like colon, stomach, lung, pancreatic, or esophageal cancer) that have a specific marker called CEA and have stopped responding to standard treatments. Researchers want to find the safest and most effective dose by testing two different ways of giving the treatment: through an IV infusion or through an injection into the abdomen.
Standard cancer treatments like chemotherapy and surgery don't work for everyone, and some patients' cancers come back or stop responding over time. This trial exists to explore whether using a patient's own immune cells—trained to specifically target cancer cells with the CEA marker—can offer a new hope for people with advanced solid tumors.
You likely qualify if…
You likely don't qualify if…
If you join this trial, your doctors will first collect immune cells from your blood through a process called apheresis (similar to donating blood). These cells will be sent to a lab where they'll be trained to recognize your cancer. Once ready, the cells will be given back to you either through an IV infusion into your arm or through an injection into your abdomen. The trial starts with small doses and gradually increases to find the safest dose. You'll have regular follow-up appointments to monitor how you're responding and check for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China